Patient Management for Medication Simplification During Care Transitions

Abstract

Transitions of care represent a period of heightened vulnerability for patients, particularly those with complex medication regimens. Medication simplification is increasingly recognized as a critical strategy to reduce polypharmacy, minimize adverse drug events, and improve adherence. This review synthesizes current evidence on medication simplification during care transitions, analyses recent guideline recommendations, and provides actionable insights for clinicians managing these complex scenarios. It aims to support healthcare professionals in optimizing pharmacotherapy, enhancing patient safety, and promoting better clinical outcomes during the crucial period of care transitions.

Introduction

Transitions in healthcare, such as hospital admission, intra-hospital transfers, or discharge to community settings, are critical junctures where medication errors and adverse events are common. Polypharmacy and regimen complexity are prevalent among patients with chronic diseases, older adults, and those requiring multidisciplinary care. Medication simplification during these transitions is not only a matter of patient convenience but also a pivotal intervention to ensure safety and efficacy. This article explores the scientific, clinical, and practical aspects of medication simplification, emphasizing evidence-based approaches for healthcare professionals.

Epidemiology / Disease Burden

Polypharmacy, typically defined as the use of five or more medications, affects up to 50% of older adults and a significant proportion of patients with multimorbidity. The prevalence is notably higher in hospitalized patients and those transitioning between care settings. Studies indicate that 20-30% of hospital readmissions are medication-related, with regimen complexity being a major contributor. The burden is further accentuated in populations with cognitive impairment, limited health literacy, or socioeconomic constraints, making medication simplification a vital clinical objective during care transitions.

Pathophysiology

The pathophysiological underpinnings of medication-related harm during care transitions involve multiple mechanisms. The interplay of pharmacokinetics, pharmacodynamics, organ dysfunction (renal, hepatic), and drug-drug interactions increases the risk of adverse effects. Complex regimens may exacerbate nonadherence, leading to subtherapeutic dosing, withdrawal syndromes, or exacerbation of underlying diseases. Furthermore, age-related physiological changes and comorbidities in older adults alter drug metabolism and sensitivity, necessitating individualized simplification strategies to mitigate risk.

Risk Factors

Several patient- and system-level factors heighten the risk of medication-related complications during transitions. Patient factors include advanced age, multiple comorbidities, cognitive or functional impairment, and previous adverse drug events. System-level risks encompass fragmented communication, inadequate medication reconciliation, and time pressures in acute care settings. Additionally, the presence of high-alert medications or drugs with narrow therapeutic indices increases the importance of simplification and careful oversight during transitions.

Clinical Features

Clinical manifestations of medication-related problems during care transitions are diverse, ranging from mild adverse drug reactions to severe events such as falls, delirium, acute organ dysfunction, or hospitalization. Patients may present with non-specific symptoms such as confusion, hypotension, unexplained bleeding, or gastrointestinal disturbances. Polypharmacy and regimen complexity are often implicated in poor adherence, therapeutic failure, and deterioration of quality of life, underscoring the need for vigilant assessment and proactive simplification strategies.

Diagnosis

Diagnosis of medication-related issues during care transitions requires systematic approaches, including comprehensive medication review, reconciliation, and the use of validated tools such as the Medication Regimen Complexity Index (MRCI). Clinical pharmacists and multidisciplinary teams play a crucial role in identifying inappropriate therapy, unnecessary duplication, and drug-drug or drug-disease interactions. Electronic health records and clinical decision support systems can further aid in detecting discrepancies and potential simplification opportunities.

Treatment & Management

Effective management during care transitions hinges on medication reconciliation, patient-centered deprescribing, and simplification of regimens without compromising therapeutic intent. Strategies include consolidating dosing schedules, switching to combination products where appropriate, and eliminating unnecessary or duplicative agents. Engaging patients and caregivers in shared decision-making, providing clear instructions, and ensuring follow-up are essential components. Clinical pharmacists should be integral to the transition process, offering expertise in pharmacotherapy optimization and risk mitigation.

Recent Advances / Emerging Therapies

Recent research highlights the efficacy of structured deprescribing protocols, digital health solutions, and pharmacist-led interventions in achieving successful medication simplification. Mobile applications and electronic medication management systems facilitate real-time communication and monitoring, reducing errors and improving adherence. Additionally, integration of artificial intelligence and predictive analytics in electronic health records is emerging as a tool to identify high-risk patients and recommend evidence-based simplification strategies tailored to individual risk profiles.

Guideline Recommendations

Recent guidelines from international bodies such as the American Geriatrics Society and the Institute for Healthcare Improvement emphasize medication review and simplification as standard practice during care transitions. Recommendations include routine use of validated assessment tools, prioritization of high-risk medications for review, and involvement of interdisciplinary teams. Guidelines also advocate for clear documentation, patient education, and post-discharge follow-up to ensure sustained benefits and minimize rehospitalization risk.

Conclusion

Medication simplification during care transitions is a cornerstone of patient safety and quality care, especially for populations vulnerable to polypharmacy and regimen complexity. Evidence-based, multidisciplinary approaches have demonstrated significant reductions in adverse drug events, improved adherence, and enhanced patient outcomes. Healthcare professionals must remain vigilant, utilize structured protocols, and engage patients in the simplification process to optimize pharmacotherapy and ensure continuity of care. Ongoing research and technological innovation will further refine these strategies, supporting safer transitions and better health outcomes across diverse care settings.